DSGN vs. OCS, CMRX, CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, and GYRE
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry.
Design Therapeutics vs. Its Competitors
Oculis (NASDAQ:OCS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.
Design Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Design Therapeutics' return on equity of -22.85% beat Oculis' return on equity.
In the previous week, Oculis had 3 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Oculis and 0 mentions for Design Therapeutics. Oculis' average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.
22.3% of Oculis shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Design Therapeutics has lower revenue, but higher earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.
Oculis presently has a consensus target price of $35.33, suggesting a potential upside of 92.03%. Design Therapeutics has a consensus target price of $4.00, suggesting a potential downside of 0.99%. Given Oculis' stronger consensus rating and higher possible upside, equities analysts clearly believe Oculis is more favorable than Design Therapeutics.
Oculis has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500.
Summary
Design Therapeutics beats Oculis on 9 of the 14 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DSGN) was last updated on 7/10/2025 by MarketBeat.com Staff
